| Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future MA Karsdal, M Michaelis, C Ladel, AS Siebuhr, AR Bihlet, JR Andersen, ... Osteoarthritis and cartilage 24 (12), 2013-2021, 2016 | 381 | 2016 |
| Extracellular matrix remodeling: the common denominator in connective tissue diseases possibilities for evaluation and current understanding of the matrix as more than a … MA Karsdal, MJ Nielsen, JM Sand, K Henriksen, F Genovese, ... Assay and drug development technologies 11 (2), 70-92, 2013 | 302 | 2013 |
| The minor collagens in articular cartilage Y Luo, D Sinkeviciute, Y He, M Karsdal, Y Henrotin, A Mobasheri, ... Protein & cell 8 (8), 560-572, 2017 | 284 | 2017 |
| Novel insights into the function and dynamics of extracellular matrix in liver fibrosis MA Karsdal, T Manon-Jensen, F Genovese, JH Kristensen, MJ Nielsen, ... American Journal of Physiology-Gastrointestinal and Liver Physiology 308 (10 …, 2015 | 264 | 2015 |
| The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments? MA Karsdal, AC Bay-Jensen, RJ Lories, S Abramson, T Spector, ... Annals of the rheumatic diseases 73 (2), 336-348, 2014 | 224 | 2014 |
| The disease modifying osteoarthritis drug (DMOAD): is it in the horizon? P Qvist, AC Bay-Jensen, C Christiansen, EB Dam, P Pastoureau, ... Pharmacological research 58 (1), 1-7, 2008 | 216 | 2008 |
| Osteoarthritis phenotypes and novel therapeutic targets WE Van Spil, O Kubassova, M Boesen, AC Bay-Jensen, A Mobasheri Biochemical pharmacology 165, 41-48, 2019 | 213 | 2019 |
| MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation–divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation BC Sondergaard, N Schultz, SH Madsen, AC Bay-Jensen, M Kassem, ... Osteoarthritis and cartilage 18 (3), 279-288, 2010 | 197 | 2010 |
| A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M) DJ Leeming, Y He, SS Veidal, QHT Nguyen, DV Larsen, M Koizumi, ... Biomarkers 16 (7), 616-628, 2011 | 194 | 2011 |
| Osteoarthritis Year in Review 2016: biomarkers (biochemical markers) A Mobasheri, AC Bay-Jensen, WE Van Spil, J Larkin, MC Levesque Osteoarthritis and cartilage 25 (2), 199-208, 2017 | 193 | 2017 |
| Recent advances in understanding the phenotypes of osteoarthritis A Mobasheri, S Saarakkala, M Finnilä, MA Karsdal, AC Bay-Jensen, ... F1000Research 8, 2019 | 192 | 2019 |
| Osteoarthritis–a case for personalized health care? MA Karsdal, C Christiansen, C Ladel, K Henriksen, VB Kraus, ... Osteoarthritis and Cartilage 22 (1), 7-16, 2014 | 174 | 2014 |
| Novel combinations of post-translational modification (PTM) neo-epitopes provide tissue-specific biochemical markers—are they the cause or the consequence of the disease? MA Karsdal, K Henriksen, DJ Leeming, T Woodworth, E Vassiliadis, ... Clinical biochemistry 43 (10-11), 793-804, 2010 | 171 | 2010 |
| Two New Single‐Nucleotide Polymorphisms in the COL1A1 Upstream Regulatory Region and Their Relationship to Bone Mineral Density N Garcia‐Giralt, X Nogués, A Enjuanes, J Puig, L Mellibovsky, ... Journal of Bone and Mineral Research 17 (3), 384-393, 2002 | 164 | 2002 |
| Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis? AC Bay-Jensen, S Hoegh-Madsen, E Dam, K Henriksen, ... Rheumatology international 30, 435-442, 2010 | 163 | 2010 |
| Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials MA Karsdal, I Byrjalsen, P Alexandersen, A Bihlet, JR Andersen, BJ Riis, ... Osteoarthritis and cartilage 23 (4), 532-543, 2015 | 161 | 2015 |
| Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM—increased serum CIIM in subjects with severe radiographic osteoarthritis AC Bay-Jensen, Q Liu, I Byrjalsen, Y Li, J Wang, C Pedersen, DJ Leeming, ... Clinical biochemistry 44 (5-6), 423-429, 2011 | 157 | 2011 |
| Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development MA Karsdal, K Henriksen, DJ Leeming, P Mitchell, K Duffin, N Barascuk, ... Biomarkers 14 (3), 181-202, 2009 | 152 | 2009 |
| Biochemical markers of ongoing joint damage in rheumatoid arthritis-current and future applications, limitations and opportunities MA Karsdal, T Woodworth, K Henriksen, WP Maksymowych, H Genant, ... Arthritis research & therapy 13, 1-20, 2011 | 146 | 2011 |
| The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases S Sun, AC Bay-Jensen, MA Karsdal, AS Siebuhr, Q Zheng, ... BMC musculoskeletal disorders 15, 1-8, 2014 | 145 | 2014 |
Morten KarsdalProfessorAdresse e-mail validée de nordicbioscience.com